New heart failure drug shows promise in Mid-Stage trial

NCT ID NCT06299826

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 14 times

Summary

This study tested a new medicine called AZD5462 in 375 adults with stable chronic heart failure. The goal was to see if the drug could improve how well the heart pumps blood. Participants took either the study drug or a placebo, and doctors measured heart function using ultrasound (echocardiography).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Alexander City, Alabama, 35010, United States
Research Site

Northridge, California, 91325, United States
Research Site

Torrance, California, 90502, United States
Research Site

Vista, California, 92081, United States
Research Site

Miami, Florida, 33133, United States
Research Site

Miami Beach, Florida, 33140, United States
Research Site

Richmond, Indiana, 47374, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Buffalo, New York, 14215, United States
Research Site

Rosedale, New York, 11422, United States
Research Site

Chapel Hill, North Carolina, 27599, United States
Research Site

Philadelphia, Pennsylvania, 19107, United States
Research Site

Knoxville, Tennessee, 37916, United States
Research Site

Manassas, Virginia, 20109, United States
Research Site

Pleven, 5800, Bulgaria
Research Site

Sofia, 1309, Bulgaria
Research Site

Sofia, 1431, Bulgaria
Research Site

Sofia, 1527, Bulgaria
Research Site

Brno, 625 00, Czechia
Research Site

Jaroměř, 55101, Czechia
Research Site

Liberec, 460 01, Czechia
Research Site

Louny, 440 01, Czechia
Research Site

Pilsen, 301 00, Czechia
Research Site

Aalborg, 9000, Denmark
Research Site

Herning, 7400, Denmark
Research Site

Balatonfüred, 8230, Hungary
Research Site

Kistarcsa, 2143, Hungary
Research Site

Nyíregyháza, 4400, Hungary
Research Site

Székesfehérvár, 8000, Hungary
Research Site

Kochi, 682018, India
Research Site

Kolkata, 700020, India
Research Site

Surat, 395001, India
Research Site

Vadodara, 390022, India
Research Site

Fukui-shi, 910-8526, Japan
Research Site

Higashiibaraki-gun, 311-3193, Japan
Research Site

Higashiohmi-shi, 527-8505, Japan
Research Site

Kitakyushu, 802-8555, Japan
Research Site

Kobe, 654-0155, Japan
Research Site

Kumamoto, 861-4193, Japan
Research Site

Miyazaki, 880-0834, Japan
Research Site

Morioka, 020-0066, Japan
Research Site

Naha, 902-8511, Japan
Research Site

Ōmihachiman, 523-0082, Japan
Research Site

Shūnan, 745-8522, Japan
Research Site

Breda, 4818 CK, Netherlands
Research Site

Deventer, 7416 SE, Netherlands
Research Site

Enschede, 7512 KZ, Netherlands
Research Site

Krakow, 30-082, Poland
Research Site

Krakow, 31-271, Poland
Research Site

Lodz, 93-513, Poland
Research Site

Warsaw, 01-249, Poland
Research Site

Wroclaw, 50-556, Poland
Research Site

Wroclaw, 50-981, Poland
Research Site

Bratislava, 813 69, Slovakia
Research Site

Bratislava, 821 07, Slovakia
Research Site

Košice, 044 24, Slovakia

Conditions

Explore the condition pages connected to this study.

CHRONIC HEART FAILURE